Search

Your search keyword '"Balercia, G"' showing total 478 results
Start Over Author "Balercia, G"
478 results on '"Balercia, G"'

101. Sexual dysfunction in subjects with Klinefelter’s syndrome

Author

Corona, G., primary, Petrone, L., additional, Paggi, F., additional, Lotti, F., additional, Boddi, V., additional, Fisher, A., additional, Vignozzi, L., additional, Balercia, G., additional, Sforza, A., additional, Forti, G., additional, Mannucci, E., additional, and Maggi, M., additional

Published
2009
Full Text
View/download PDF

104. Phenotypic variation within European carriers of the Y-chromosomal gr/gr deletion is independent of Y-chromosomal background

Author

Krausz, C, primary, Giachini, C, additional, Xue, Y, additional, O'Bryan, M K, additional, Gromoll, J, additional, Meyts, E R.-d., additional, Oliva, R, additional, Aknin-Seifer, I, additional, Erdei, E, additional, Jorgensen, N, additional, Simoni, M, additional, Ballesca, J L, additional, Levy, R, additional, Balercia, G, additional, Piomboni, P, additional, Nieschlag, E, additional, Forti, G, additional, McLachlan, R, additional, and Tyler-Smith, C, additional

Published
2008
Full Text
View/download PDF

116. Have androgen receptor gene CAG and GGC repeat polymorphisms an effect on sperm motility in infertile men?

Author

delli Muti, N., Agarwal, A., Buldreghini, E., Gioia, A., Lenzi, A., Boscaro, M., and Balercia, G.

Subjects
SPERMATOGENESIS, ANDROGENS, PSYCHOLOGY, MALE infertility, POLYGLUTAMINE, ANDROGEN receptors
Abstract

Androgens and a normal androgen receptor ( AR) are required for normal spermatogenesis. We investigated polyglutamine ( CAG) and a polyglycine ( GGC) tract in Italian men with defective spermatogenesis. We studied a group of 40 infertile men with spermatogenesis failure without Y-chromosome microdeletions compared with 60 normozoospermic ones. The distributions of both polymorphisms, within the normal range of Caucasian populations, were similar among infertile men and controls. Nonetheless, we observed that the frequency comparison of each CAG allele showed a statistical difference in the allele CAG 22; GGC 17 was the more predominant allele in infertile men than in controls. Moreover, to investigate the hypothesis that semen characteristics are perturbed by androgen receptor allele variants, we tried to detect a link between triplets and sperm motility in all subjects (cases plus controls). Subjects were subdivided into three groups, based on calculated allele frequencies. A significantly decreased motility, related to a longer CAG and GGC tracts, and marked differences between the groups exist for both polymorphisms. Our data highlight a probable relationship between the allele CAG 22/ GGC 17 and a defective spermatogenesis in infertile men, suggesting that these polymorphisms might have an important effect on AR function. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

120. An update of Coenzyme Q_{10} implications in male infertility: Biochemical and therapeutic aspects.

Author

Mancini, A., De Marinis, L., Littarru, G. P., and Balercia, G.

Subjects
COENZYMES, MALE infertility, SPERMATOZOA, HUMAN fertility, GENITAL diseases, UBIQUINONES, REACTIVE oxygen species, PHOTOSYNTHETIC oxygen evolution
Abstract

This review is focused upon the role of coenzyme Q_{10} in male infertility in the light of a broader issue of oxidative damage and antioxidant defence in sperm cells and seminal plasma. Reactive oxygen species play a key pathogenetic role in male infertility besides having a well-recognized physiological function. The deep involvement of coenzyme _{10} in mitochondrial bioenergetics and its antioxidant properties are at the basis of its role in seminal fluid. Following the early studies addressing its presence in sperm cells and seminal plasma, the relative distribution of the quinone between these two compartments was studied in infertile men, with special attention to varicocele. The reduction state of CoQ_{10} in seminal fluid was also investigated. After the first in vitro experiments CoQ_{10} was administered to a group of idiopathic asthenozoospermic infertile patients. Seminal analysis showed a significant increase of CoQ_{10} both in seminal plasma and in sperm cells, together with an improvement in sperm motility. The increased concentration of CoQ_{10} in seminal plasma and sperm cells, the improvement of semen kinetic features after treatment, and the evidence of a direct correlation between CoQ_{10} concentrations and sperm motility strongly support a cause/effect relationship. From a general point of view, a deeper knowledge of these molecular mechanisms could lead to a new insight into the so-called unexplained infertility. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

123. Coenzyme Q10and male infertility

Author

Balercia, G., Mancini, A., Paggi, F., Tiano, L., Pontecorvi, A., Boscaro, M., Lenzi, A., and Littarru, G.

Abstract

We had previously demonstrated that Coenzyme Q10[(CoQ10) also commonly called ubiquinone]is present in well-measurable levels in human seminal fluid, where it probably exerts important metabolic and antioxidant functions; seminal CoQ10concentrations show a direct correlation with seminal parameters (count and motility). Alterations of CoQ10content were also shown in conditions associated with male infertility, such as asthenozoospermia and varicocele (VAR). The physiological role of this molecule was further clarified by inquiring into its variations in concentrations induced by different medical or surgical procedures used in male infertility treatment. We therefore evaluated CoQ10concentration and distribution between seminal plasma and spermatozoa in VAR, before and after surgical treatment, and in infertile patients after recombinant human FSH therapy. The effect of CoQ10on sperm motility and function had been addressed only through some in vitroexperiments. In two distinct studies conducted by our group, 22 and 60 patients affected by idiopathic asthenozoospermia were enrolled, respectively. CoQ10and its reduced form, ubiquinol, increased significantly both in seminal plasma and sperm cells after treatment, as well as spermatozoa motility. A weak linear dependence among the relative variations, at baseline and after treatment, of seminal plasma or intracellular CoQ10, ubiquinol levels and kinetic parameters was found in the treated group. Patients with lower baseline value of motility and CoQ10levels had a statistically significant higher probability to be responders to the treatment. In conclusion, the exogenous administration of CoQ10increases both ubiquinone and ubiquinol levels in semen and can be effective in improving sperm kinetic features in patients affected by idiopathic asthenozoospermia

Published
2009
Full Text
View/download PDF

124. Laurdan

Author

Ambrosini, A., Zolese, G., Balercia, G., Bertoli, E., Arnaldi, G., and Mantero, F.

Published
2001
Full Text
View/download PDF

126. Enhanced activity of peritoneal cells after aclacinomycin injection: effect of pretreatment with superoxide dismutase on aclacinomycin-induced cytological alterations and antitumoral activity

Author

Bravo-Cuellar, A., Balercia, G., Jean-Pierre Levesque, Liu, X. H., Osculati, F., and Orbach-Arbouys, S.

Subjects
Cytotoxicity, Immunologic, Lipopolysaccharides, Male, Superoxide Dismutase, Macrophages, Neoplasms, Experimental, Mice, Inbred C57BL, Mice, Mice, Inbred DBA, Talc, Luminescent Measurements, Animals, Aclarubicin, Peritoneal Cavity
Abstract

Peritoneal macrophages from mice injected with aclacinomycin (ACM) (4 mg/kg, i.p.) showed increased functional activity, as assessed by increased antitumoral activity in vitro and in vivo and zymosan-triggered chemoluminescence. They also showed ultrastructural signs of activation (increased number of cytoplasmic organelles), and atypical alterations (giant vacuoles and giant lysosomes containing heterogenous myelinoid bodies, lipofuscine-like substance, cytoplasmic debris, and a fine granular material). As these atypical alterations could be due to the generation of superoxide following ACM injection, superoxide dismutase (SOD) was injected 1 h prior to ACM administration. Neither the morphological characteristics of activation, nor the enhanced metabolic and antitumoral activities induced by ACM were affected by SOD pretreatment, but the atypical alterations were inhibited in a dose-dependent manner. Heat-inactivated SOD did not prevent their appearance. The atypical alterations were not found in peritoneal macrophages from talc or lipopolysaccharide-injected mice, but they were present in Adriamycin-treated mice and were also prevented by SOD pretreatment, indicating that the alterations are due to anthracycline treatment. Finally, [125I]SOD was phagocytized by peritoneal macrophages in vitro and in vivo and not by L1210 tumoral cells, explaining why the atypical alterations induced by ACM were no longer seen after SOD pretreatment. The unchanged direct oncostatic activity of ACM following SOD pretreatment suggests that this combination may have some wider perhaps clinical, potential.

127. Defects of steroidogenesis

Author

Biason-Lauber, A., Boscaro, M., Mantero, F., Balercia, G., Biason-Lauber, A., Boscaro, M., Mantero, F., and Balercia, G.

Abstract

In the biosynthesis of steroid hormones the neutral lipid cholesterol, a normal constituent of lipid bilayers is transformed via a series of hydroxylation, oxidation, and reduction steps into a vast array of biologically active compounds: mineralocorticoids, glucocorticoids, and sex hormones. Glucocorticoids regulate many aspects of metabolism and immune function, whereas mineralocorticoids help maintain blood volume and control renal excretion of electrolytes. Sex hormones are essential for sex differentiation in male and support reproduction. They include androgens, estrogens, and progestins. A block in the pathway of steroid biosynthesis leads to the lack of hormones downstream and accumulation of the upstream compounds that can activate other members of the steroid receptor family. This review deals with the clinical consequences of these blocks

131. Risk behaviours and alcohol in adolescence are negatively associated with testicular volume: results from the Amico-Andrologo survey

Author

Patrizio Pasqualetti, Andrea Garolla, Giancarlo Balercia, Daniele Santi, A. R. M. Granata, Alberto Ferlin, Rosario Pivonello, Andrea Lenzi, A.M. Sinisi, Daniele Gianfrilli, Andrea M. Isidori, Fabio Lanfranco, Andrea Sansone, Mario Maggi, Carlo Foresta, Gianfrilli, D, Ferlin, A, Isidori, A M, Garolla, A, Maggi, M, Pivonello, R, Santi, D, Sansone, A, Balercia, G, Granata, A R M, Sinisi, A, Lanfranco, F, Pasqualetti, P, Foresta, C, Lenzi, A, Gianfrilli, D., Ferlin, A., Isidori, A. M., Garolla, A., Maggi, M., Pivonello, R., Santi, D., Sansone, A., Balercia, G., Granata, A. R. M., Sinisi, A., Lanfranco, F., Pasqualetti, P., Foresta, C., and Lenzi, A.

Subjects
Male, Adolescent, Alcohol Drinking, Substance-Related Disorders, Urology, Endocrinology, Diabetes and Metabolism, Sexual Behavior, health risk behaviour, Overweight, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Settore MED/13, Risk-Taking, prevention, Recall bias, Sexual medicine, health risk behaviours, Surveys and Questionnaires, Premature ejaculation, Testis, medicine, Humans, Sexual Maturation, adolescence, alcohol, andrological health, testicular development, Reproductive health, 030219 obstetrics & reproductive medicine, business.industry, Smoking, adolescence, alcohol, andrological health, health risk behaviours, prevention, testicular development, Reproductive Health, Reproductive Medicine, Genital Diseases, Cohort, medicine.symptom, Underweight, Genital Diseases, Male, business, Demography, Adolescent health
Abstract

Background Risk factors established during adolescence affect health outcomes in adulthood, although little is known about how adolescent health risk behaviours (HRBs) affect testicular development and reproductive health. Objectives To assess prevalence of HRBs among last year high school students; to describe the most prevalent andrological disorders in this cohort; to explore HRBs associated with andrological disorders and investigate factors possibly associated with impaired testicular development in puberty. Materials and methods The Amico-Andrologo Survey is a permanent nationwide surveillance programme conducted by the Italian Society of Andrology and Sexual Medicine and supported by the Ministry of Health. A nationally representative survey of final-year male high school students was conducted using a validated structured interview (n = 10124) and medical examination (n = 3816). Results Smoking (32.6%), drinking (80.6%) and use of illegal drugs (46.5%) are common in adolescence. 16.6% of subjects were overweight, 3.1% were underweight and 2.3% were obese. Among sexually active students (60.3%), unprotected sex was very common (48.3%). Only 11.6% had been treated for andrological disorders, despite an abnormal clinical examination in 34.6%. Bilateral testicular hypotrophy (14.0%), varicocoele (27.1%) and phimosis (7.1%) were the most prevalent disorders; 5.1% complained of premature ejaculation and 4.7% had an STI. Underweight and heavy alcohol or drug use were associated with testicular hypotrophy. HRBs emerged as significant predictors of testicular hypotrophy, explaining up to 9.6% of its variance. Limitations include risk of selection bias for voluntary physical examination and recall bias for the self-compiled questionnaire. Discussion There is an emerging global adverse trend of HRBs in male high school students. A significant proportion of adolescent males with unsuspected andrological disorders engage in behaviours that could impair testicular development. Conclusion Greater attention to the prevention of andrological health in adolescence is needed.

Published
2019

132. Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism

Author

Andrea Lenzi, Mariano Galdiero, Francesco Lombardo, Antonio F. Radicioni, Riccardo Selice, Antonio Bellastella, Mario Maggi, Carlo Foresta, Gianni Forti, Annamaria Colao, Andrea Fabbri, Csilla Krausz, Loredana Gandini, Antonio Agostino Sinisi, Giancarlo Balercia, Gaetano Lombardi, Lenzi, A., Balercia, G., Bellastella, Antonio, Colao, Annamaria, Fabbri, A., Foresta, C., Galdiero, Mariano, Gandini, L., Krausz, C., Lombardi, Gaetano, Lombardo, F., Maggi, M., Radicioni, A., Selice, R., Sinisi, ANTONIO AGOSTINO, Forti, G., Lenzi, A, Balercia, G, Bellastella, A, Colao, A, Fabbri, A, Foresta, C, Galdiero, M, Gandini, L, Krausz, C, Lombardi, G, Lombardo, F, Maggi, M, Radicioni, A, Selice, R, and Sinisi, Antonio Agostino

Subjects
Adult, Male, medicine.medical_specialty, Hormone Replacement Therapy, medicine.drug_class, Endocrinology, Diabetes and Metabolism, functional hypogonadotropic hypogonadism, male hypogonadotropic hypogonadism, Context (language use), Physical exercise, Chorionic Gonadotropin, male infertility, Male infertility, Settore MED/13, Endocrinology, Hypogonadotropic hypogonadism, Internal medicine, medicine, Humans, Endocrine system, Child, functional hypogoradotropic hypogonadism, Testosterone, business.industry, Hypogonadism, Puberty, hypogonadotropic hypogonadism, Follicle Stimulating Hormone, fsh, testosterone, medicine.disease, Gonadotropin secretion, Gonadotropin, business
Abstract

Hypogonadotropic hypogonadism (HH), or secondary hypogonadism, is a clinical condition due to an impairment of the pituitary function, characterized by low testosterone plasma levels associated with normal or low FSH and LH plasma levels. An impairment of gonadotropin secretion and, therefore, a reduced efficiency of spermatogenesis was reported to be frequently associated to conditions different from the classical causes of secondary hypogonadism. These conditions (metabolic, endocrine and eating disorders, physical exercise etc.) have been associated with a non-classical form of HH that could be called "functional" HH (FHH). FHH differs from the classical one by the evidence that gonadotropin levels are in the low-normal range, but are inadequate for the testosterone levels, that often are also in the low-normal range. This commentary aims at reviewing knowledge on the forms of male HH in order to indicate and discuss clinical context, diagnostic and therapeutic approach in the less known non-classical form, i.e. FHH.

Published
2009

133. Consensus and Diversity in the Management of Varicocele for Male Infertility: Results of a Global Practice Survey and Comparison with Guidelines and Recommendations

Author

Shah, Rupin, Agarwal, Ashok, Kavoussi, Parviz, Rambhatla, Amarnath, Saleh, Ramadan, Cannarella, Rossella, Harraz, Ahmed M., Boitrelle, Florence, Kuroda, Shinnosuke, Hamoda, Taha Abo-Almagd Abdel-Meguid, Zini, Armand, Ko, Edmund, Çalık, Gökhan, Toprak, Tuncay, Kandil, Hussein, Gül, Murat, Bakırcıoğlu, Mustafa Emre, Parekh, Neel, Russo, Giorgio Ivan, Tadros, Nicholas, Kadıoğlu, Ateş, Arafa, Mohamed, Chung, Eric, Rajmil, Osvaldo, Dimitriadis, Fotios, Malhotra, Vineet, Salvio, Gianmaria, Henkel, Ralf, Le, Tan V., Sogutdelen, Emrullah, Vij, Sarah, Alarbid, Abdullah, Güdeloğlu, Ahmet, Tsujimura, Akira, Calogero, Aldo E., El Meliegy, Amr, Crafa, Andrea, Kalkanlı, Arif, Baser, Aykut, Hazır, Berk, Giulioni, Carlo, Cho, Chak-Lam, Ho, Christopher C.K., Salzano, Ciro, Zylbersztejn, Daniel Suslik, Tien, Dung Mai Ba, Pescatori, Edoardo, Borges, Edson, Saïs-Hamza, Eminej, Huyghe, Eric, Ceyhan, Erman, Caroppo, Ettore, Castiglioni, Fabrizio, Bahar, Fahmi, Gökalp, Fatih, Lombardo, Francesco, Gadda, Franco, Duarsa, Gede Wirya Kusuma, Pinggera, Germar-Michael, Busetto, Gian Maria, Balercia, Giancarlo, Cito, Gianmartin, Blecher, Gideon, Franco, Giorgio, Liguori, Giovanni, Elbardisi, Haitham, Keskin, Hakan, Lin, Haocheng, Taniguchi, Hisanori, Park, Hyun Jun, Ziouziou, Imad, de la Rosette, Jean J. M. C. H., Hotaling, Jim, Ramsay, Jonathan, Molina, Juan Manuel Corral, Lo, Ka Lun, Böcü, Kadir, Khalafalla, Kareim, Bowa, Kasonde, Okada, Keisuke, Nagao, Koichi, Chiba, Koji, Hakim, Lukman, Makarounis, Konstantinos, Hehemann, Marah, Peña, Marcelo Rodriguez, Falcone, Marco, Bendayan, Marion, Martinez, Marlon, Timpano, Massimiliano, Altan, Mesut, Fode, Mikkel, Al-Marhoon, Mohamed S., Gilani, Mohammad Ali Sadighi, Soebadi, Mohammad Ayodhia, Gherabi, Nazim, Sofikitis, Nikolaos, Kahraman, Oğuzhan, Birowo, Ponco, Kothari, Priyank, Sindhwani, Puneet, Javed, Qaisar, Ambar, Rafael F., Kosgi, Raghavender, Ghayda, Ramy Abou, Adriansjah, Ricky, Condorelli, Rosita Angela, La Vignera, Sandro, Micic, Sava, Kim, Shannon Hee Kyung, Fukuhara, Shinichiro, Ahn, Sun Tae, Mostafa, Taymour, Ong, Teng Aik, Takeshima, Teppei, Amano, Toshiyasu, Barrett, Trenton, Arslan, Umut, Karthikeyan, Vilvapathy Senguttuvan, Atmoko, Widi, Yumura, Yasushi, Yuan, Yiming, Kato, Yuki, Jezek, Davor, Cheng, Bryan Kwun-Chung, Hatzichristodoulou, Georgios, Dy, Jun, Castañé, Eduard Ruiz, El-Sakka, Ahmed I., Nguyen, Quang, Sarıkaya, Selçuk, Boeri, Luca, Tan, Ronny, Moussa, Mohamad A., El-Assmy, Ahmed, Alali, Hamed, Alhathal, Naif, Osman, Yasser, Perovic, Dragoljub, Sajadi, Hesamoddin, Akhavizadegan, Hamed, Vučinić, Miroslav, Kattan, Said, Kattan, Mohamed S., Mogharabian, Nasser, Phuoc, Nguyen Ho Vinh, Ngoo, Kay Seong, Alkandari, Mohammad H., Alsuhaibani, Shaheed, Sokolakis, Ioannis, Babaei, Mehdi, King, Mak Siu, Diemer, Thorsten, Gava, Marcelo M., Henrique, Raphael, Spinola e Silva, Rodrigo, Paul, Gustavo Marquesine, Mierzwa, Tiago Cesar, Glina, Sidney, Siddiqi, Kashif, Wu, Han, Wurzacher, Jana, Farkouh, Ala'a, Son, Hwancheol, Minhas, Suks, Lee, Joe, Magsanoc, Nikko, Capogrosso, Paolo, Albano, German Jose, Lewis, Sheena E.M., Jayasena, Channa N., Alvarez, Juan G., Teo, Colin, Smith, Ryan P., Chua, Jo Ben M., Jensen, Christian Fuglesang S., Parekattil, Sijo, Finelli, Renata, Durairajanayagam, Damayanthi, Karna, Keshab Kumar, Ahmed, Abdelkareem, Evenson, Don, Umemoto, Yukihiro, Puigvert, Ana, Çeker, Gökhan, Colpi, Giovanni M., Rolitsky, Sarah, Bouzouita, Abderrazak, Shokeir, Ahmed, Aşçı, Ahmet, Bouker, Amin, Adamyan, Aram, Avoyan, Armen E., Palani, Ayad, Aghamajidi, Azin, Eze, Balantine, Noegroho, Bambang Sasongko, Purnomo, Basuki, Erkan, Bircan Kolbaşı, Zilaitiene, Birute, Kulaksız, Deniz, Kafetzis, Dimitrios, Lee, Dong Sup, Stember, Doron, Evgeni, Evangelini, Alhajeri, Faisal, Finocchi, Federica, Colombo, Fulvio, Tsangaris, George, Sallam, Hassan N., Acosta, Herik, Rosas, Israel Maldonado, Kirkman-Brown, Jackson, Shin, Jae Il, Sonksen, Jens, Dong, Jie, Marmar, Joel, Moreno-Sepulveda, Jose, Seo, Ju Tae, Aydos, Kaan, Kesari, Kavindra Kumar, Trost, Landon, Jenkins, Lawrence, Rocco, Lucia, Darbandi, Mahsa, Simopoulou, Mara, Alves, Marco, Sabbaghian, Marjan, Tavalaee, Marziyeh, Razi, Mazdak, Duran, Mesut Berkan, Nago, Mitsuru, Elkhouly, Mohamed, Khalili, Mohamed, Nasr-Esfahani, Mohammad Hossein, Kamath, Mohan S., Uğur, Muhammet Raşit, Park, Nam Cheol, Cruz, Natalio, Garrido, Nicolas, Sodeifi, Niloofar, Al Khalidi, Noora, Shoshany, Ohad, Satyagraha, Paksi, Drakopoulos, Panagiotos, Vogiatzi, Paraskevi, Dolati, Parisa, Das, Partha, Chiu, Peter Ka-Fung, Tsioulou, Petroula A., Patel, Premal, Singh, Rajender, Kaiyal, Raneen Sawaid, Santos, Ferreira, Dada, Rima, Brodjonegoro, Sakti, Banihani, Saleem Ali, Schon, Samantha, Darbandi, Sara, Güneş, Sezgin, Homa, Sheryl, Mutambirwa, Shingai, Roychoudhury, Shubhadeep, Diaz, Sofia Ines Leonardi, Gopalakrishnan, Sreelatha, Krawetz, Stephen, Jindal, Sunil, Avidor-Reiss, Tomer, Lin, Tsung Yen, Kumar, Vijay, Ibrahim, Wael, Kerkeni, Walid, Woo, Wongi, Morimoto, Yoshiharu, Cheng, Yu-Sheng, Shah, Rupin, Agarwal, Ashok, Kavoussi, Parviz, Rambhatla, Amarnath, Saleh, Ramadan, Cannarella, Rossella, Harraz, Ahmed M., Boitrelle, Florence, Kuroda, Shinnosuke, Hamoda, Taha Abo-Almagd Abdel-Meguid, Zini, Armand, Ko, Edmund, Calik, Gokhan, Toprak, Tuncay, Kandil, Hussein, Gül, Murat, Bakırcıoğlu, Mustafa Emre, Parekh, Neel, Russo, Giorgio Ivan, Tadros, Nichola, Kadioglu, Ate, Arafa, Mohamed, Chung, Eric, Rajmil, Osvaldo, Dimitriadis, Fotio, Malhotra, Vineet, Salvio, Gianmaria, Henkel, Ralf, Le, Tan V., Sogutdelen, Emrullah, Vij, Sarah, Alarbid, Abdullah, Gudeloglu, Ahmet, Tsujimura, Akira, Calogero, Aldo E., Meliegy, Amr El, Crafa, Andrea, Kalkanli, Arif, Baser, Aykut, Hazir, Berk, Giulioni, Carlo, Cho, Chak-Lam, Ho, Christopher C. K., Salzano, Ciro, Zylbersztejn, Daniel Suslik, Tien, Dung Mai Ba, Pescatori, Edoardo, Borges, Edson, Serefoglu, Ege Can, Sas-Hamza, Emine, Huyghe, Eric, Ceyhan, Erman, Caroppo, Ettore, Castiglioni, Fabrizio, Bahar, Fahmi, Gokalp, Fatih, Lombardo, Francesco, Gadda, Franco, Duarsa, Gede Wirya Kusuma, Pinggera, Germar-Michael, Busetto, Gian Maria, Balercia, Giancarlo, Cito, Gianmartin, Blecher, Gideon, Franco, Giorgio, Liguori, Giovanni, Elbardisi, Haitham, Keskin, Hakan, Lin, Haocheng, Taniguchi, Hisanori, Park, Hyun Jun, Ziouziou, Imad, Rosette, Jean de la, Hotaling, Jim, Ramsay, Jonathan, Molina, Juan Manuel Corral, Lo, Ka Lun, Bocu, Kadir, Khalafalla, Kareim, Bowa, Kasonde, Okada, Keisuke, Nagao, Koichi, Chiba, Koji, Hakim, Lukman, Makarounis, Konstantino, Hehemann, Marah, Peña, Marcelo Rodriguez, Falcone, Marco, Bendayan, Marion, Martinez, Marlon, Timpano, Massimiliano, Altan, Mesut, Fode, Mikkel, Al-Marhoon, Mohamed S., Gilani, Mohammad Ali Sadighi, Soebadi, Mohammad Ayodhia, Gherabi, Nazim, Sofikitis, Nikolao, Kahraman, Oğuzhan, Birowo, Ponco, Kothari, Priyank, Sindhwani, Puneet, Javed, Qaisar, Ambar, Rafael F., Kosgi, Raghavender, Ghayda, Ramy Abou, Adriansjah, Ricky, Condorelli, Rosita Angela, Vignera, Sandro La, Micic, Sava, Kim, Shannon Hee Kyung, Fukuhara, Shinichiro, Ahn, Sun Tae, Mostafa, Taymour, Ong, Teng Aik, Takeshima, Teppei, Amano, Toshiyasu, Barrett, Trenton, Arslan, Umut, Karthikeyan, Vilvapathy Senguttuvan, Atmoko, Widi, Yumura, Yasushi, Yuan, Yiming, Kato, Yuki, Jezek, Davor, Cheng, Bryan Kwun-Chung, Hatzichristodoulou, Georgio, Dy, Jun, Castañé, Eduard Ruiz, El-Sakka, Ahmed I., Nguyen, Quang, Sarikaya, Selcuk, Boeri, Luca, Tan, Ronny, Moussa, Mohamad A., El-Assmy, Ahmed, Alali, Hamed, Alhathal, Naif, Osman, Yasser, Perovic, Dragoljub, Sajadi, Hesamoddin, Akhavizadegan, Hamed, Vučinić, Miroslav, Kattan, Said, Kattan, Mohamed S., Mogharabian, Nasser, Phuoc, Nguyen Ho Vinh, Ngoo, Kay Seong, Alkandari, Mohammad H., Alsuhaibani, Shaheed, Sokolakis, Ioanni, Babaei, Mehdi, King, Mak Siu, Diemer, Thorsten, Gava, Marcelo M., Henrique, Raphael, Silva, Rodrigo Spinola e, Paul, Gustavo Marquesine, Mierzwa, Tiago Cesar, Glina, Sidney, Siddiqi, Kashif, Wu, Han, Wurzacher, Jana, Farkouh, Ala’A, Son, Hwancheol, Minhas, Suk, Lee, Joe, Magsanoc, Nikko, Capogrosso, Paolo, Albano, German Jose, Lewis, Sheena E. M., Jayasena, Channa N., Alvarez, Juan G., Teo, Colin, Smith, Ryan P., Chua, Jo Ben M., Jensen, Christian Fuglesang S., Parekattil, Sijo, Finelli, Renata, Durairajanayagam, Damayanthi, Karna, Keshab Kumar, Ahmed, Abdelkareem, Evenson, Don, Umemoto, Yukihiro, Puigvert, Ana, Çeker, Gökhan, Forum, Giovanni M Colpi, Shah, R., Agarwal, A., Kavoussi, P., Rambhatla, A., Saleh, R., Cannarella, R., Harraz, A. M., Boitrelle, F., Kuroda, S., Hamoda, T. A. -A. A. -M., Zini, A., Ko, E., Calik, G., Toprak, T., Kandil, H., Gul, M., Bakircioglu, M. E., Parekh, N., Russo, G. I., Tadros, N., Kadioglu, A., Arafa, M., Chung, E., Rajmil, O., Dimitriadis, F., Malhotra, V., Salvio, G., Henkel, R., Le, T. V., Sogutdelen, E., Vij, S., Alarbid, A., Gudeloglu, A., Tsujimura, A., Calogero, A. E., El Meliegy, A., Crafa, A., Kalkanli, A., Baser, A., Hazir, B., Giulioni, C., Cho, C. -L., Ho, C. C. K., Salzano, C., Zylbersztejn, D. S., Tien, D. M. B., Pescatori, E., Borges, E., Serefoglu, E. C., Sais-Hamza, E., Huyghe, E., Ceyhan, E., Caroppo, E., Castiglioni, F., Bahar, F., Gokalp, F., Lombardo, F., Gadda, F., Duarsa, G. W. K., Pinggera, G. -M., Busetto, G. M., Balercia, G., Cito, G., Blecher, G., Franco, G., Liguori, G., Elbardisi, H., Keskin, H., Lin, H., Taniguchi, H., Park, H. J., Ziouziou, I., de la Rosette, J., Hotaling, J., Ramsay, J., Molina, J. M. C., Lo, K. L., Bocu, K., Khalafalla, K., Bowa, K., Okada, K., Nagao, K., Chiba, K., Hakim, L., Makarounis, K., Hehemann, M., Pena, M. R., Falcone, M., Bendayan, M., Martinez, M., Timpano, M., Altan, M., Fode, M., Al-Marhoon, M. S., Gilani, M. A. S., Soebadi, M. A., Gherabi, N., Sofikitis, N., Kahraman, O., Birowo, P., Kothari, P., Sindhwani, P., Javed, Q., Ambar, R. F., Kosgi, R., Ghayda, R. A., Adriansjah, R., Condorelli, R. A., La Vignera, S., Micic, S., Kim, S. H. K., Fukuhara, S., Ahn, S. T., Mostafa, T., Ong, T. A., Takeshima, T., Amano, T., Barrett, T., Arslan, U., Karthikeyan, V. S., Atmoko, W., Yumura, Y., Yuan, Y., Kato, Y., Jezek, D., Cheng, B. K. -C., Hatzichristodoulou, G., Dy, J., Castane, E. R., El-Sakka, A. I., Nguyen, Q., Sarikaya, S., Boeri, L., Tan, R., Moussa, M. A., El-Assmy, A., Alali, H., Alhathal, N., Osman, Y., Perovic, D., Sajadi, H., Akhavizadegan, H., Vucinic, M., Kattan, S., Kattan, M. S., Mogharabian, N., Phuoc, N. H. V., Ngoo, K. S., Alkandari, M. H., Alsuhaibani, S., Sokolakis, I., Babaei, M., King, M. S., Diemer, T., Gava, M. M., Henrique, R., Spinola e Silva, R., Paul, G. M., Mierzwa, T. C., Glina, S., Siddiqi, K., Wu, H., Wurzacher, J., Farkouh, A., Son, H., Minhas, S., Lee, J., Magsanoc, N., Capogrosso, P., Albano, G. J., Lewis, S. E. M., Jayasena, C. N., Alvarez, J. G., Teo, C., Smith, R. P., Chua, J. B. M., Jensen, C. F. S., Parekattil, S., Finelli, R., Durairajanayagam, D., Karna, K. K., Ahmed, A., Evenson, D., Umemoto, Y., Puigvert, A., Ceker, G., Colpi, G. M., Rolitsky, S., Bouzouita, A., Shokeir, A., Asci, A., Bouker, A., Adamyan, A., Avoyan, A. E., Palani, A., Aghamajidi, A., Eze, B., Noegroho, B. S., Purnomo, B., Erkan, B. K., Zilaitiene, B., Kulaksiz, D., Kafetzis, D., Lee, D. S., Stember, D., Evgeni, E., Alhajeri, F., Finocchi, F., Colombo, F., Tsangaris, G., Sallam, H. N., Acosta, H., Rosas, I. M., Kirkman-Brown, J., Shin, J. I., Sonksen, J., Dong, J., Marmar, J., Moreno-Sepulveda, J., Seo, J. T., Aydos, K., Kesari, K. K., Trost, L., Jenkins, L., Rocco, L., Darbandi, M., Simopoulou, M., Alves, M., Sabbaghian, M., Tavalaee, M., Razi, M., Duran, M. B., Nago, M., Elkhouly, M., Khalili, M., Nasr-Esfahani, M. H., Kamath, M. S., Ugur, M. R., Park, N. C., Cruz, N., Garrido, N., Sodeifi, N., Al Khalidi, N., Shoshany, O., Satyagraha, P., Drakopoulos, P., Vogiatzi, P., Dolati, P., Das, P., Chiu, P. K. -F., Tsioulou, P. A., Patel, P., Singh, R., Kaiyal, R. S., Santos, F., Dada, R., Brodjonegoro, S., Banihani, S. A., Schon, S., Darbandi, S., Gunes, S., Homa, S., Mutambirwa, S., Roychoudhury, S., Diaz, S. I. L., Gopalakrishnan, S., Krawetz, S., Jindal, S., Avidor-Reiss, T., Lin, T. Y., Kumar, V., Ibrahim, W., Kerkeni, W., Woo, W., Morimoto, Y., Cheng, Y. -S., and Tıp Fakültesi

Subjects
Aging, Consensus, Urology, INGUINAL VARICOCELECTOMY, Disease management, Male infertility, Survey, Varicocele, Consensu, Global Andrology Forum, Endocrinology & Metabolism, NONOBSTRUCTIVE AZOOSPERMIA, ASSISTED REPRODUCTIVE TECHNOLOGY, Male Infertility, Pharmacology (medical), Andrology, IMPAIRED SEMEN QUALITY, EUROPEAN ASSOCIATION, Science & Technology, UROLOGY GUIDELINES, Health Policy, Public Health, Environmental and Occupational Health, Disease Management, Urology & Nephrology, SUBCLINICAL VARICOCELE, Psychiatry and Mental health, Health Care Sciences & Services, MICROSURGICAL SUBINGUINAL VARICOCELECTOMY, Reproductive Medicine, SPERM MORPHOLOGY, UNTREATED VARICOCELE, Life Sciences & Biomedicine
Abstract

Purpose: Varicocele is a common problem among infertile men. Varicocele repair (VR) is frequently performed to improve semen parameters and the chances of pregnancy. However, there is a lack of consensus about the diagnosis, indications for VR and its outcomes. The aim of this study was to explore global practice patterns on the management of varicocele in the context of male infertility. Materials and Methods: Sixty practicing urologists/andrologists from 23 countries contributed 382 multiple-choice-questions pertaining to varicocele management. These were condensed into an online questionnaire that was forwarded to clinicians involved in male infertility management through direct invitation. The results were analyzed for disagreement and agreement in practice patterns and, compared with the latest guidelines of international professional societies (American Urological As- sociation [AUA], American Society for Reproductive Medicine [ASRM], and European Association of Urology [EAU]), and with evidence emerging from recent systematic reviews and meta-analyses. Additionally, an expert opinion on each topic was provided based on the consensus of 16 experts in the field. Results: The questionnaire was answered by 574 clinicians from 59 countries. The majority of respondents were urologists/ uro-andrologists. A wide diversity of opinion was seen in every aspect of varicocele diagnosis, indications for repair, choice of technique, management of sub-clinical varicocele and the role of VR in azoospermia. A significant proportion of the re- sponses were at odds with the recommendations of AUA, ASRM, and EAU. A large number of clinical situations were identi- fied where no guidelines are available. Conclusions: This study is the largest global survey performed to date on the clinical management of varicocele for male in- fertility. It demonstrates: 1) a wide disagreement in the approach to varicocele management, 2) large gaps in the clinical prac- tice guidelines from professional societies, and 3) the need for further studies on several aspects of varicocele management in infertile men.

Published
2022

134. Antisperm Antibody Testing: A Comprehensive Review of Its Role in the Management of Immunological Male Infertility and Results of a Global Survey of Clinical Practices

Author

Sajal Gupta, Rakesh Sharma, Ashok Agarwal, Florence Boitrelle, Renata Finelli, Ala'a Farkouh, Ramadan Saleh, Taha Abo-Almagd Abdel-Meguid, Murat Gül, Birute Zilaitiene, Edmund Ko, Amarnath Rambhatla, Armand Zini, Kristian Leisegang, Shinnosuke Kuroda, Ralf Henkel, Rossella Cannarella, Ayad Palani, Chak-Lam Cho, Christopher C.K. Ho, Daniel Suslik Zylbersztejn, Edoardo Pescatori, Eric Chung, Fotios Dimitriadis, Germar-Michael Pinggera, Gian Maria Busetto, Giancarlo Balercia, Gianmaria Salvio, Giovanni M. Colpi, Gökhan Çeker, Hisanori Taniguchi, Hussein Kandil, Hyun Jun Park, Israel Maldonado Rosas, Jean de la Rosette, Joao Paulo Greco Cardoso, Jonathan Ramsay, Juan Alvarez, Juan Manuel Corral Molina, Kareim Khalafalla, Kasonde Bowa, Kelton Tremellen, Evangelini Evgeni, Lucia Rocco, Marcelo Gabriel Rodriguez Peña, Marjan Sabbaghian, Marlon Martinez, Mohamed Arafa, Mohamed S. Al-Marhoon, Nicholas Tadros, Nicolas Garrido, Osvaldo Rajmil, Pallav Sengupta, Paraskevi Vogiatzi, Parviz Kavoussi, Ponco Birowo, Raghavender Kosgi, Saleem Bani-Hani, Sava Micic, Sijo Parekattil, Sunil Jindal, Tan V. Le, Taymour Mostafa, Tuncay Toprak, Yoshiharu Morimoto, Vineet Malhotra, Azin Aghamajidi, Damayanthi Durairajanayagam, Rupin Shah, Gupta, S., Sharma, R., Agarwal, A., Boitrelle, F., Finelli, R., Farkouh, A., Saleh, R., Abdel-Meguid, T. A. -A., Gul, M., Zilaitiene, B., Ko, E., Rambhatla, A., Zini, A., Leisegang, K., Kuroda, S., Henkel, R., Cannarella, R., Palani, A., Cho, C. -L., Ho, C. C. K., Zylbersztejn, D. S., Pescatori, E., Chung, E., Dimitriadis, F., Pinggera, G. -M., Busetto, G. M., Balercia, G., Salvio, G., Colpi, G. M., Ceker, G., Taniguchi, H., Kandil, H., Park, H. J., Rosas, I. M., de la Rosette, J., Cardoso, J. P. G., Ramsay, J., Alvarez, J., Molina, J. M. C., Khalafalla, K., Bowa, K., Tremellen, K., Evgeni, E., Rocco, L., Pena, M. G. R., Sabbaghian, M., Martinez, M., Arafa, M., Al-Marhoon, M. S., Tadros, N., Garrido, N., Rajmil, O., Sengupta, P., Vogiatzi, P., Kavoussi, P., Birowo, P., Kosgi, R., Bani-Hani, S., Micic, S., Parekattil, S., Jindal, S., Le, T. V., Mostafa, T., Toprak, T., Morimoto, Y., Malhotra, V., Aghamajidi, A., Durairajanayagam, D., and Shah, R.

Subjects
Aging, Urology, Antibodie, DIAGNOSIS, Antibodies, Endocrinology & Metabolism, male, FERTILIZATION, FERTILITY, Pharmacology (medical), Andrology, Survey, PREDNISOLONE TREATMENT, COUPLES, Science & Technology, Health Policy, Public Health, Environmental and Occupational Health, CHRONIC PROSTATITIS, Urology & Nephrology, SEMEN PARAMETERS, Infertility, male, Sperm agglutination, Spermatozoa, digestive system diseases, Psychiatry and Mental health, PREGNANCY RATES, Health Care Sciences & Services, surgical procedures, operative, Reproductive Medicine, Infertility, SPERM AUTOANTIBODIES, Life Sciences & Biomedicine, SUBFERTILE MEN
Abstract

Antisperm antibodies (ASA), as a cause of male infertility, have been detected in infertile males as early as 1954. Multiple causes of ASA production have been identified, and they are due to an abnormal exposure of mature germ cells to the immune system. ASA testing (with mixed anti-globulin reaction, and immunobead binding test) was described in the WHO manual 5th edition and is most recently listed among the extended semen tests in the WHO manual 6th edition. The relationship between ASA and infertility is somewhat complex. The presence of sperm agglutination, while insufficient to diagnose immunological infertility, may indicate the presence of ASA. However, ASA can also be present in the absence of any sperm agglutination. The andrological management of ASA depends on the etiology and individual practices of clinicians. In this article, we provide a comprehensive review of the causes of ASA production, its role in immunological male infertility, clinical indications of ASA testing, and the available therapeutic options. We also provide the details of laboratory procedures for assessment of ASA together with important measures for quality control. Additionally, laboratory and clinical scenarios are presented to guide the reader in the management of ASA and immunological male infertility. Furthermore, we report the results of a recent worldwide survey, conducted to gather information about clinical practices in the management of immunological male infertility.

Published
2022

135. First baseline data of the Klinefelter ItaliaN Group (KING) cohort: clinical features of adult with Klinefelter syndrome in Italy

Author

D, Pasquali, P, Chiodini, V, Simeon, A, Ferlin, L, Vignozzi, G, Corona, F, Lanfranco, V, Rochira, A E, Calogero, M, Bonomi, R, Pivonello, G, Balercia, A, Pizzocaro, V A, Giagulli, P, Salacone, A, Aversa, G, Accardo, M, Maggi, A, Lenzi, A, Isidori, C, Foresta, E A, Jannini, A, Garolla, Pasquali, D, Chiodini, P, Simeon, V, Ferlin, A, Vignozzi, L, Corona, G, Lanfranco, F, Rochira, V, Calogero, A E, Bonomi, M, Pivonello, R, Balercia, G, Pizzocaro, A, Giagulli, V A, Salacone, P, Aversa, A, Accardo, G, Maggi, M, Lenzi, A, Isidori, A, Foresta, C, Jannini, E A, and Garolla, A

Subjects
Male, LH, BMI, FSH, Klinefelter syndrome, MetS, Metabolic syndrome, Testis, Testosterone, Endocrinology, Diabetes and Metabolism, Hypogonadism, Klinefelter syndrome, Metabolic syndrome, MetS, Testosterone, Testis, BMI, LH, FSH, Settore MED/13 - Endocrinologia, Endocrinology, Testi, Humans, Follicle Stimulating Hormone
Abstract

Background Klinefelter syndrome (KS) is frustratingly under-diagnosed. KS have a broad spectrum of clinical features, making it difficult to identify. Objective We describe KS clinical presentation in a large Italian cohort. Design This is the first observational cohort study within a national network, the Klinefelter ItaliaN Group (KING). Primary outcomes were to describe the basic clinical features and the actual phenotype of KS in Italy. Secondary outcomes were to determine age at diagnosis and geographical distribution. Methods We performed a basic phenotyping and evaluation of the hormonal values of 609 adult KS patients. Results Mean age at diagnosis was 37.4 ± 13.4 years. The overall mean testicular size was 3 ml, and 2.5 ml in both testes in untreated KS group. BMI was 26.6 ± 5.8 kg/m2, and 25.5% of KS had metabolic syndrome (MetS). LH and FSH were increased, and mean total testosterone were 350 ± 9.1 ng/dl. A descriptive analysis showed that 329 KS patients were evaluated in Northern Italy, 76 in Central and 204 in Southern Italy. Analysis of variance demonstrated significant statistical differences (p Conclusions These data are the results of the only national database available that collects the clinical and hormonal data of the KS patients, currently referred at the KING centers. In Italy the typical KS patient is overweight, with small testes, and elevated LH and FSH. Only 25.5% of them are diagnosed with MetS. Early detection and timely treatment are mandatory.

Published
2022

136. Diabetes mellitus and late-onset hypogonadism: the role of Glu298Asp endothelial nitric oxide synthase polymorphism.

Author

delli Muti, N., Tirabassi, G., Lamonica, G. R., Lenzi, A., and Balercia, G.

Subjects
*HYPOGONADISM, *TYPE 2 diabetes risk factors, *NITRIC oxide synthesis, *INSULIN resistance, *SINGLE nucleotide polymorphisms, *DIAGNOSIS
Abstract

Nitric oxide has been associated with insulin resistance and type 2 diabetes mellitus (DM). An association has been suggested between a single nucleotide polymorphism (Glu298Asp variant) of the endothelial nitric oxide synthase ( eNOS) gene and increased risk of DM. However, the role of this polymorphism in favouring DM has not been investigated in hypogonadism, in which low testosterone and obesity are believed to play the major role. We aimed to evaluate whether eNOS gene single nucleotide polymorphism (Glu298Asp variant) might give a relevant contribution also to the onset of hypogonadism-associated DM. 110 men affected by late-onset hypogonadism were retrospectively reviewed. Patients were clinically and biochemically evaluated. Detection of eNOS Glu298Asp polymorphism was performed. After splitting the sample according to the three genetic variants (i.e. eNOSGG, eNOSGT, eNOSTT), no difference was evident in age, body mass index (BMI) and total testosterone. Conversely, DM prevalence, glycaemia and glycated haemoglobin were significantly higher in eNOSTT than in eNOSGT and eNOSGG. Logistic regression analysis showed that, after adjustment for age, BMI and total testosterone, eNOSTT was positively and significantly associated with DM. Our study suggests that Glu298Asp single nucleotide polymorphism of the eNOS gene may be an independent risk factor for hypogonadism-associated type 2 DM. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

137. Vitamin D and thyroid disease: to D or not to D?

Author

Muscogiuri, G, Tirabassi, G, Bizzaro, G, Orio, F, Paschou, S A, Vryonidou, A, Balercia, G, Shoenfeld, Y, and Colao, A

Subjects
*THYROID diseases, *VITAMIN D in human nutrition, *HOMEOSTASIS, *ENDOCRINE diseases, *POLYCYSTIC ovary syndrome, *DIABETES
Abstract

The main role of vitamin D is to maintain calcium and phosphorus homeostasis, thus preserving bone health. Recent evidence has demonstrated that vitamin D may also have a role in a variety of nonskeletal disorders such as endocrine diseases and in particular type 1 diabetes, type 2 diabetes, adrenal diseases and polycystic ovary syndrome. Low levels of vitamin D have also been associated with thyroid disease, such as Hashimoto's thyroiditis. Similarly, patients with new-onset Graves' disease were found to have decreased 25-hydroxyvitamin D concentrations. Impaired vitamin D signaling has been reported to encourage thyroid tumorigenesis. This review will focus on the role of vitamin D in thyroid diseases, both autoimmune diseases and thyroid cancer, and will summarize the results of vitamin D supplementation studies performed in patients with thyroid disorders. Although observational studies support a beneficial role of vitamin D in the management of thyroid disease, randomized controlled trials are required to provide insight into the efficacy and safety of vitamin D as a therapeutic tool for this dysfunction. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

138. Human leucocytes in asthenozoospermic patients: endothelial nitric oxide synthase expression.

Author

Buldreghini, E., Hamada, A., Macrì, M. L., Amoroso, S., Boscaro, M., Lenzi, A., Agarwal, A., and Balercia, G.

Subjects
*LEUCOCYTES, *SPERM motility, *ENDOTHELIAL cells, *NITRIC-oxide synthases, *GENE expression, *ANDROLOGY
Abstract

In a basic study at the Andrology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy, we evaluated the pattern of mRNA endothelial nitric oxide synthase ( eNOS) expression in human blood leucocytes isolated from normozoospermic fertile and asthenozoospermic infertile men to elucidate any pathogenic involvement in sperm cell motility. Forty infertile men with idiopathic asthenozoospermia and 45 normozoospermic fertile donors, age-matched, were included. Semen parameters were evaluated, and expression analysis of mRNA was performed in human leucocytes using reverse transcription polymerase chain reaction. Sperm volume, count, motility and morphology were determined, and eNOS expression and Western blotting analyses were performed. A positive correlation was observed between the concentrations of NO and the percentage of immotile spermatozoa. The mRNA of eNOS was more expressed in peripheral blood leucocytes isolated from asthenozoospermic infertile men versus those of fertile normozoospermic men (7.46 ± 0.38 versus 7.06 ± 0.56, P = 0.0355). A significant up-regulation of eNOS gene in peripheral blood leucocytes was 1.52-fold higher than that of fertile donors. It is concluded that eNOS expression and activity are enhanced in blood leucocytes in men with idiopathic asthenozoospermia. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

141. Vitamin D and Male Sexual Function: A Transversal and Longitudinal Study

Author

Giovanni Corona, Giovanna Muscogiuri, Giacomo Tirabassi, Maurizio Sudano, Gianmaria Salvio, Melissa Cutini, Giancarlo Balercia, Tirabassi, G., Sudano, M., Salvio, G., Cutini, M., Muscogiuri, G., Corona, G., and Balercia, G.

Subjects
Longitudinal study, D SUPPLEMENTATION, Article Subject, Endocrinology, Diabetes and Metabolism, Physiology, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, Logistic regression, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, D DEFICIENCY, 0302 clinical medicine, Endocrinology, D-RECEPTOR, ERECTILE DYSFUNCTION, TESTOSTERONE, Vitamin D and neurology, Medicine, lcsh:RC648-665, DYSREGULATION, Free testosterone, Endocrine and Autonomic Systems, business.industry, Testosterone (patch), Erectile function, PREVALENCE, HYPOGONADISM, business, Sexual function, Male sexual function, Research Article
Abstract

Background. The effects of vitamin D on sexual function are very unclear. Therefore, we aimed at evaluating the possible association between vitamin D and sexual function and at assessing the influence of vitamin D administration on sexual function. Methods. We retrospectively studied 114 men by evaluating clinical, biochemical, and sexual parameters. A subsample (n=41) was also studied longitudinally before and after vitamin D replacement therapy. Results. In the whole sample, after performing logistic regression models, higher levels of 25(OH) vitamin D were significantly associated with high values of total testosterone and of all the International Index of Erectile Function (IIEF) questionnaire parameters. On the other hand, higher levels of total testosterone were positively and significantly associated with high levels of erectile function and IIEF total score. After vitamin D replacement therapy, total and free testosterone increased and erectile function improved, whereas other sexual parameters did not change significantly. At logistic regression analysis, higher levels of vitamin D increase (Δ-) were significantly associated with high values of Δ-erectile function after adjustment for Δ-testosterone. Conclusions. Vitamin D is important for the wellness of male sexual function, and vitamin D administration improves sexual function.

Published
2018
Full Text
View/download PDF

142. GLP-1: benefits beyond pancreas

Author

G, Muscogiuri, A, Cignarelli, F, Giorgino, F, Prodam, F, Prodram, D, Santi, G, Tirabassi, G, Balercia, R, Modica, A, Faggiano, A, Colao, Muscogiuri, Giovanna, Cignarelli, A, Giorgino, F, Prodram, F, Santi, D, Tirabassi, G, Balercia, G, Modica, R, Faggiano, Antongiulio, and Colao, Annamaria

Subjects
cardiovascular risk, endocrine system, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Central nervous system, Type 2 diabetes, Biology, Bone remodeling, body weight, Endocrinology, Glucagon-Like Peptide 1, Risk Factors, Internal medicine, Diabetes mellitus, Bone cell, medicine, Animals, Humans, Obesity, Receptor, Pancreas, Kidney, nervous system, digestive, oral, and skin physiology, medicine.disease, medicine.anatomical_structure, GLP1, pancreas, Diabetes Mellitus, Type 2, Cardiovascular Diseases, hormones, hormone substitutes, and hormone antagonists
Abstract

Introduction: Glucagon-like peptide 1 (GLP-1) is an intestinal hormone secreted after the ingestion of various nutrients. The main role of GLP-1 is to stimulate insulin secretion in a glucose-dependent manner. However, the expression of GLP-1 receptor was found to be expressed in a variety of tissues beyond pancreas such as lung, stomach, intestine, kidney, heart and brain. Beyond pancreas, a beneficial effect of GLP-1 on body weight reduction has been shown, suggesting its role for the treatment of obesity. In addition, GLP-1 has been demonstrated to reduce cardiovascular risk factors and to have a direct cardioprotective effect, fostering heart recovery after ischemic injury. Further, data from both experimental animal models and human studies have shown beneficial effect of GLP-1 on bone metabolism, either directly or indirectly on bone cells. Materials and methods: We review here the recent findings of the extra-pancreatic effects of GLP-1 focusing on both basic and clinical studies, thus opening future perspectives to the use of GLP-1 analogs for the treatment of disease beyond type 2 diabetes. Conclusion: Finally, the GLP-1 has been demonstrated to have a beneficial effect on both vascular, degenerative diseases of central nervous system and psoriasis.

Published
2014

143. Vitamin D and thyroid disease: To D or not to D?

Author

Giacomo Tirabassi, Y Shoenfeld, Giovanna Muscogiuri, Andromachi Vryonidou, Giancarlo Balercia, Annamaria Colao, F Orio, Giorgia Bizzaro, Stavroula A Paschou, Muscogiuri, Giovanna, Tirabassi, G., Bizzaro, G., Orio, Francesco, Paschou, S. A., Vryonidou, A., Balercia, G., Shoenfeld, Y., and Colao, Annamaria

Subjects
medicine.medical_specialty, endocrine system, endocrine system diseases, Thyroid Disease, Medicine (miscellaneous), Type 2 diabetes, Disease, Hashimoto Disease, Thyroiditis, Vitamin, Internal medicine, medicine, Vitamin D and neurology, Nutrition and Dietetic, Humans, Thyroid Neoplasms, Vitamin D, Thyroid cancer, Thyroid Neoplasm, Dietary Supplement, Nutrition and Dietetics, business.industry, Thyroid disease, Medicine (all), Thyroid, Vitamins, medicine.disease, Vitamin D Deficiency, Polycystic ovary, Thyroid Diseases, Graves Disease, Endocrinology, medicine.anatomical_structure, Dietary Supplements, business, Human
Abstract

The main role of vitamin D is to maintain calcium and phosphorus homeostasis, thus preserving bone health. Recent evidence has demonstrated that vitamin D may also have a role in a variety of nonskeletal disorders such as endocrine diseases and in particular type 1 diabetes, type 2 diabetes, adrenal diseases and polycystic ovary syndrome. Low levels of vitamin D have also been associated with thyroid disease, such as Hashimoto's thyroiditis. Similarly, patients with new-onset Graves' disease were found to have decreased 25-hydroxyvitamin D concentrations. Impaired vitamin D signaling has been reported to encourage thyroid tumorigenesis. This review will focus on the role of vitamin D in thyroid diseases, both autoimmune diseases and thyroid cancer, and will summarize the results of vitamin D supplementation studies performed in patients with thyroid disorders. Although observational studies support a beneficial role of vitamin D in the management of thyroid disease, randomized controlled trials are required to provide insight into the efficacy and safety of vitamin D as a therapeutic tool for this dysfunction.

Published
2015

144. Erratum to: GLP-1: Benefits beyond pancreas

Author

Roberta Modica, Giovanna Muscogiuri, Antongiulio Faggiano, A. Colao, Flavia Prodam, Angelo Cignarelli, Giacomo Tirabassi, Daniele Santi, Francesco Giorgino, Giancarlo Balercia, Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodam, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., and Colao, A.

Subjects
medicine.medical_specialty, Endocrinology, medicine.anatomical_structure, business.industry, Endocrinology, Diabetes and Metabolism, Internal medicine, medicine, Pancreas, business
Published
2015

145. Consensus statement on diagnosis and clinical management of Klinefelter syndrome

Author

Linda Vignozzi, Giancarlo Balercia, Carlo Foresta, Alberto Ferlin, Antonio F. Radicioni, Andrea Lenzi, Mario Maggi, Daniela Pasquali, Radicioni, Af, Ferlin, A, Balercia, G, Pasquali, Daniela, Vignozzi, L, Maggi, M, Foresta, C, and Lenzi, A.

Subjects
Infertility, Adult, Male, medicine.medical_specialty, Pathology, Adolescent, Statement (logic), Endocrinology, Diabetes and Metabolism, MEDLINE, Endocrinology, Cognition, Klinefelter Syndrome, Sexual medicine, Epidemiology, medicine, Diabetes Mellitus, hypogonadism, Humans, aneuploidy, Child, Gonadal Steroid Hormones, Metabolic Syndrome, rare diseases, testosterone, infertility, klinefelter syndrome, epidemiology, business.industry, Puberty, Infant, Newborn, medicine.disease, Infant newborn, Family medicine, Osteoporosis, Klinefelter syndrome, business
Abstract

Nearly 70 years after its description, Klinefelter syndrome (KS) remains a largely undiagnosed condition. As its clinical presentation may be subtle, many of those affected may be unaware or diagnosed only during evaluation for hypogonadism and/or infertility. In February 2010 an interdisciplinary panel of specialists met in Abano Terme (Padua, Italy) in a workshop on "Klinefelter Syndrome: diagnosis and clinical management". The main aim of this meeting was to discuss several aspects related to the epidemiology, pathogenesis, and evaluation of KS and to develop a consensus defining its early diagnosis and treatment. In the present consensus we have highlighted the features that may prompt the physicians to look after patients with KS both for the syndrome and correlated diseases. We have provided evidences that, during the different phases of life, there might be some advantages in establishing the diagnosis and starting proper follow-up and treatment. The workshop was carried out under the auspices of the Italian Society of andrology and Sexual Medicine (SIAMS).

Published
2011

146. Pembrolizumab-induced Thyroiditis, Hypophysitis and Adrenalitis: A Case of Triple Endocrine Dysfunction.

Author

Rossi S, Silvetti F, Bordoni M, Ciarloni A, Salvio G, and Balercia G

Abstract

Immune checkpoint inhibitor drugs can trigger autoimmune endocrine reactions as a known side effect. Several cases of immunotherapy-induced autoimmune endocrinopathies have been described, but multiple sequential endocrine toxicities are a rare occurrence. A 39-year-old patient with metastatic melanoma started adjuvant therapy with pembrolizumab. One month later he presented with asymptomatic thyrotoxicosis and, within several weeks, overt hypothyroidism, for which he started levothyroxine therapy. Subsequently the patient developed central adrenal insufficiency due to probable hypophysitis, and steroid replacement therapy was started. Pembrolizumab therapy was then discontinued. After a few months, a full recovery of pituitary function was observed, but primary adrenal insufficiency occurred, requiring additional fludrocortisone therapy. The described clinical case is a very uncommon case of triple endocrinological toxicity from immunotherapy. The clinical and biochemical manifestations of immunotherapy-induced endocrinopathies can be variable and atypical; therefore, it is necessary to pay special attention to any clue of hormonal dysfunction., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.)

Published
2024
Full Text
View/download PDF

147. Hypogonadotropic hypogonadism as a cause of NOA and its treatment.

Author

Salvio G, Balercia G, and Kadioglu A

Abstract

Abstract: Hypogonadotropic hypogonadism (HH) represents a relatively rare cause of nonobstructive azoospermia (NOA), but its knowledge is crucial for the clinical andrologists, as it represents a condition that can be corrected with medical therapy in 3 quarters of cases. There are forms of congenital HH, whether or not associated with an absent sense of smell (anosmic HH or Kallmann syndrome, and normosmic HH, respectively), and forms of acquired HH. In congenital HH, complete absence of pubertal development is characteristic. On the other hand, if the deficit occurs after the time of pubertal development, as in acquired HH patients, infertility and typical symptoms of late-onset hypogonadism are the main reasons for seeking medical assistance. Gonadotropin-releasing hormone (GnRH) or gonadotropin replacement therapy is the mainstay of drug therapy and offers excellent results, although a small but significant proportion of patients do not achieve sufficient responses., (Copyright © 2024 Copyright: ©The Author(s)(2024).)

Published
2024
Full Text
View/download PDF

148. Global Practice Patterns in the Evaluation of Non-Obstructive Azoospermia: Results of a World-Wide Survey and Expert Recommendations.

Author

Shah R, Rambhatla A, Atmoko W, Martinez M, Ziouziou I, Kothari P, Tadros N, Phuoc NHV, Kavoussi P, Harraz A, Salvio G, Gul M, Hamoda T, Toprak T, Birowo P, Ko E, Arafa M, Ghayda RA, Karthikeyan VS, Saleh R, Russo GI, Pinggera GM, Chung E, Savira M, Colpi GM, Zohdy W, Pescatori E, Park HJ, Fukuhara S, Tsujimura A, Rojas-Cruz C, Marino A, Mak SK, Amar E, Ibrahim W, Sindhwani P, Alhathal N, Busetto GM, Al Hashimi M, El-Sakka A, Ramazan A, Dimitriadis F, Timpano M, Jezek D, Altay B, Zylbersztejn DS, Wong MY, Moon DG, Wyns C, Gamidov S, Akhavizadegan H, Franceschelli A, Aydos K, Quang VN, Ashour S, Al Dayel A, Al-Marhoon MS, Micic S, Binsaleh S, Hussein A, Elbardisi H, Mostafa T, Taha E, Ramsay J, Zachariou A, Abdelrahman IFS, Rajmil O, Kalkanli A, Molina JMC, Bocu K, Duarsa GWK, Ceker G, Serefoglu EC, Bahar F, Gherabi N, Kuroda S, Bouzouita A, Gudeloglu A, Ceyhan E, Hasan MSM, Musa MU, Motawi A, Chak-Lam C, Taniguchi H, Ho CCK, Vazquez JFS, Mutambirwa S, Gungor ND, Bendayan M, Giulioni C, Baser A, Falcone M, Boeri L, Blecher G, Kheradmand A, Sethupathy T, Adriansjah R, Narimani N, Konstantinidis C, Nguyen TT, Japari A, Dolati P, Singh K, Ozer C, Sarikaya S, Sheibak N, Bosco NJ, Özkent MS, Le ST, Sokolakis I, Katz D, Smith R, Truong MN, Le TV, Huang Z, Deger MD, Arslan U, Calik G, Franco G, Rashed A, Kahraman O, Andreadakis S, Putra R, Balercia G, Khalafalla K, Cannarella R, Tuấn AĐ, El Meliegy A, Zilaitiene B, Ramirez MLZ, Giacone F, Calogero AE, Makarounis K, Jindal S, Hoai BN, Banthia R, Peña MR, Moorthy D, Adamyan A, Kulaksiz D, Kandil H, Sofikitis N, Salzano C, Jungwirth A, Banka SR, Mierzwa TC, Turunç T, Jain D, Avoyan A, Salacone P, Kadıoğlu A, Gupta C, Lin H, Shamohammadi I, Mogharabian N, Barrett T, Danacıoğlu YO, Crafa A, Daoud S, Malhotra V, Almardawi A, Selim OM, Moussa M, Haghdani S, Duran MB, Kunz Y, Preto M, Eugeni E, Nguyen T, Elshahid AR, Suyono SS, Parikesit D, Nada E, Orozco EG, Boitrelle F, Trang NTM, Jamali M, Nair R, Ruzaev M, Gadda F, Thomas C, Ferreira RH, Gul U, Maruccia S, Kanbur A, Kinzikeeva E, Abumelha S, Quang N, Kosgi R, Gokalp F, Soebadi MA, Paul GM, Sajadi H, Gupte D, Ambar RF, Sogutdelen E, Singla K, Basurkano A, Kim SHK, Gilani MAS, Nagao K, Brodjonegoro SR, Rezano A, Elkhouly M, Mazzilli R, Farsi HMA, Ba HN, Alali H, Kafetzis D, Long TQT, Alsaid S, Cuong HBN, Oleksandr K, Mustafa A, Acosta H, Pai H, Şahin B, Arianto E, Teo C, Jayaprakash SP, Rachman RI, Yenice MG, Sefrioui O, Paghdar S, Priyadarshi S, Tanic M, Alfatlawy NK, Rizaldi F, Vishwakarma RB, Kanakis G, Cherian DT, Lee J, Galstyan R, Keskin H, Wurzacher J, Seno DH, Noegroho BS, Margiana R, Javed Q, Castiglioni F, Tanwar R, Puigvert A, Kaya C, Purnomo M, Yazbeck C, Amir A, Borges E, Bellavia M, Deswanto IA, V VK, Liguori G, Minh DH, Siddiqi K, Colombo F, Zini A, Patel N, Çayan S, Al-Kawaz U, Ragab M, Hebrard GH, Hoffmann I, Efesoy O, Saylam B, and Agarwal A

Abstract

Purpose: Non-obstructive azoospermia (NOA) represents the persistent absence of sperm in ejaculate without obstruction, stemming from diverse disease processes. This survey explores global practices in NOA diagnosis, comparing them with guidelines and offering expert recommendations., Materials and Methods: A 56-item questionnaire survey on NOA diagnosis and management was conducted globally from July to September 2022. This paper focuses on part 1, evaluating NOA diagnosis. Data from 367 participants across 49 countries were analyzed descriptively, with a Delphi process used for expert recommendations., Results: Of 336 eligible responses, most participants were experienced attending physicians (70.93%). To diagnose azoospermia definitively, 81.7% requested two semen samples. Commonly ordered hormone tests included serum follicle-stimulating hormone (FSH) (97.0%), total testosterone (92.9%), and luteinizing hormone (86.9%). Genetic testing was requested by 66.6%, with karyotype analysis (86.2%) and Y chromosome microdeletions (88.3%) prevalent. Diagnostic testicular biopsy, distinguishing obstructive azoospermia (OA) from NOA, was not performed by 45.1%, while 34.6% did it selectively. Differentiation relied on physical examination (76.1%), serum hormone profiles (69.6%), and semen tests (68.1%). Expectations of finding sperm surgically were higher in men with normal FSH, larger testes, and a history of sperm in ejaculate., Conclusions: This expert survey, encompassing 367 participants from 49 countries, unveils congruence with recommended guidelines in NOA diagnosis. However, noteworthy disparities in practices suggest a need for evidence-based, international consensus guidelines to standardize NOA evaluation, addressing existing gaps in professional recommendations., Competing Interests: The authors have nothing to disclose., (Copyright © 2024 Korean Society for Sexual Medicine and Andrology.)

Published
2024
Full Text
View/download PDF

149. Pro-Osteogenic Effect of the Nutraceutical BlastiMin Complex ® in Women with Osteoporosis or Osteopenia: An Open Intervention Clinical Trial.

Author

Sabatelli S, Scarpa ES, Giuliani A, Giordani C, Sabbatinelli J, Rippo MR, Cabodi S, Petrini B, Balercia G, and Giacchetti G

Subjects
Humans, Female, Aged, Middle Aged, Mesenchymal Stem Cells metabolism, Mesenchymal Stem Cells drug effects, Biomarkers, Osteoblasts metabolism, Osteoblasts drug effects, Bone Remodeling drug effects, Bone Diseases, Metabolic drug therapy, Bone Diseases, Metabolic etiology, Bone Diseases, Metabolic metabolism, Dietary Supplements, Bone Density drug effects, Osteogenesis drug effects, Osteoporosis drug therapy, Osteoporosis metabolism
Abstract

Osteoporosis is a chronic disease that affects millions of patients worldwide and is characterized by low bone mineral density (BMD) and increased risk of fractures. Notably, natural molecules can increase BMD and exert pro-osteogenic effects. Noteworthily, the nutraceutical BlastiMin Complex ® (Mivell, Italy, European Patent Application EP4205733A1) can induce differentiation of human bone marrow mesenchymal stem cells (BM-MSCs) in osteoblasts and can exert in vitro pro-osteogenic and anti-inflammatory effects. Thus, the purpose of this study was to verify the effects of BlastiMin Complex ® on bone turnover markers (BTMs) and BMD in patients with senile and postmenopausal osteopenia or osteoporosis. The efficacy of BlastiMin Complex ® on BTMs in serum was evaluated through biochemical assays. BMD values were analyzed by dual-energy X-ray absorptiometry (DXA) and Radiofrequency Echographic Multi Spectrometry (R.E.M.S.) techniques, and the SNPs with a role in osteoporosis development were evaluated by PCR. Clinical data obtained after 12 months of treatment showed an increase in bone turnover index, a decrease in C-reactive protein levels, and a remarkable increase in P1NP levels, indicating the induction of osteoblast proliferation and activity in the cohort of 100% female patients recruited for the study. These findings show that the nutraceutical BlastiMin Complex ® could be used as an adjuvant in combination with synthetic drugs for the treatment of osteoporosis pathology.

Published
2024
Full Text
View/download PDF

150. Antioxidant, Anti-Inflammatory, Anti-Diabetic, and Pro-Osteogenic Activities of Polyphenols for the Treatment of Two Different Chronic Diseases: Type 2 Diabetes Mellitus and Osteoporosis.

Author

Scarpa ES, Antonelli A, Balercia G, Sabatelli S, Maggi F, Caprioli G, Giacchetti G, and Micucci M

Subjects
Humans, Animals, Osteogenesis drug effects, Oxidative Stress drug effects, Chronic Disease, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 metabolism, Polyphenols pharmacology, Polyphenols chemistry, Polyphenols therapeutic use, Osteoporosis drug therapy, Osteoporosis metabolism, Antioxidants pharmacology, Antioxidants therapeutic use, Antioxidants chemistry, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents therapeutic use, Hypoglycemic Agents pharmacology, Hypoglycemic Agents chemistry, Hypoglycemic Agents therapeutic use
Abstract

Polyphenols are natural bioactives occurring in medicinal and aromatic plants and food and beverages of plant origin. Compared with conventional therapies, plant-derived phytochemicals are more affordable and accessible and have no toxic side effects. Thus, pharmaceutical research is increasingly inclined to discover and study new and innovative natural molecules for the treatment of several chronic human diseases, like type 2 diabetes mellitus (T2DM) and osteoporosis. These pathological conditions are characterized by a chronic inflammatory state and persistent oxidative stress, which are interconnected and lead to the development and worsening of these two health disorders. Oral nano delivery strategies have been used to improve the bioavailability of polyphenols and to allow these natural molecules to exert their antioxidant, anti-inflammatory, anti-diabetic, and pro-osteogenic biological activities in in vivo experimental models and in patients. Polyphenols are commonly used in the formulations of nutraceuticals, which can counteract the detrimental effects of T2DM and osteoporosis pathologies. This review describes the polyphenols that can exert protective effects against T2DM and osteoporosis through the modulation of specific molecular markers and pathways. These bioactives could be used as adjuvants, in combination with synthetic drugs, in the future to develop innovative therapeutic strategies for the treatment of T2DM and osteoporosis.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results